Document Detail

Intracerebral hemorrhage associated with oral anticoagulant therapy: current practices and unresolved questions.
MedLine Citation:
PMID:  16339459     Owner:  NLM     Status:  MEDLINE    
BACKGROUND AND PURPOSE: Life-threatening intracranial hemorrhage, predominantly intracerebral hemorrhage (ICH), is the most serious complication of oral anticoagulant therapy (OAT), with mortality in excess of 50%. Early intervention focuses on rapid correction of coagulopathy in order to prevent continued bleeding. SUMMARY OF REVIEW: This article reviews the epidemiology of OAT-associated ICH (OAT-ICH), and current treatment options, with the aim of providing a framework for future studies of unresolved questions. A number of acute treatments are available, but all have a significant risk of inducing thrombosis and other side effects, and vary in their rapidity of effect: vitamin K (very slow response time), fresh frozen plasma (slow response time, large volume of fluid required, transfusion-related acute lung injury), prothrombin complex concentrates, and recombinant activated factor VII. Current practice is to administer a combination of vitamin K and either fresh frozen plasma or prothrombin complex concentrates; the occasional use of recombinant activated factor VII has been reported. No prospective study has addressed the efficacy of, or outcomes from, the use of these practices. CONCLUSIONS: Current management of OAT-ICH is varied and not based on evidence from randomized controlled trials. Well-designed clinical trials are essential if we are to identify the effective acute treatments for OAT-ICH that are urgently needed.
Thorsten Steiner; Jonathan Rosand; Michael Diringer
Related Documents :
21897549 - Fine needle aspiration cytology of a case of micropapillary variant of urothelial carci...
21655989 - The earwax-associated snp c.538g>a (g180r) in abcc11 is not associated with breast canc...
21892209 - An integrated genomic approach identifies arid1a as a candidate tumor-suppressor gene i...
21708019 - Association of rad51 polymorphism with dna repair in brca1 mutation carriers and sporad...
17461789 - Identification of a flavin-monooxygenase as the s-oxygenating enzyme in aliphatic gluco...
22064079 - Early dynamic versus late static lymphoscintigraphy for the identification of sentinel ...
21649789 - Verrucous carcinoma of the lip: an unusual kissing type.
8785369 - The assessment of multiple variables on breast carcinoma fine needle aspiration (fna) c...
17224269 - Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(...
Publication Detail:
Type:  Journal Article; Review     Date:  2005-12-08
Journal Detail:
Title:  Stroke; a journal of cerebral circulation     Volume:  37     ISSN:  1524-4628     ISO Abbreviation:  Stroke     Publication Date:  2006 Jan 
Date Detail:
Created Date:  2005-12-23     Completed Date:  2006-02-21     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0235266     Medline TA:  Stroke     Country:  United States    
Other Details:
Languages:  eng     Pagination:  256-62     Citation Subset:  IM    
Department of Neurology, University of Heidelberg, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Administration, Oral
Anticoagulants / administration & dosage,  adverse effects*
Cerebral Hemorrhage / chemically induced*,  therapy*
Clinical Trials as Topic
Factor VIIa / metabolism
Hemorrhage / chemically induced,  therapy
Recombinant Proteins / therapeutic use
Thrombosis / etiology
Vitamin K / metabolism
Reg. No./Substance:
0/Anticoagulants; 0/Recombinant Proteins; 12001-79-5/Vitamin K; EC VIIa

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Long-term outcome after stroke: evaluating health-related quality of life using utility measurements...
Next Document:  Telemedicine-guided carotid and transcranial ultrasound: a pilot feasibility study.